Effect of initiating use of an insulin pump in adults with type 1 diabetes using multiple daily insulin injections and continuous glucose monitoring (DIAMOND): a multicentre, randomised controlled trial
The DOI matches its Crossref record; 15 of the 16 references it cites were found in a registry or an index.
Abstract
Background The benefit of initiation of insulin pump therapy (continuous subcutaneous insulin infusion; CSII) in patients with type 1 diabetes using continuous glucose monitoring (CGM) has not been studied. We aimed to assess glycaemic outcomes when switching from multiple daily injections (MDI) to CSII in adults with type 1 diabetes using CGM.Methods In this multicentre, randomised controlled trial, 75 adults with type 1 diabetes in the CGM group of the DIAMOND trial were randomly assigned via the study website using a computer-generated sequence to continue MDI or switch to CSII, with continuation of CGM, for 28 weeks. The primary outcome was CGM-measured time in the glucose concentration range of 70-180 mg/dL (3·9-10·0 mmol/L). This study is registered with ClinicalTrials.gov, number NCT02282397.Findings Between April 14, 2015, and May 5, 2016, 37 participants were randomly assigned to the CGM plus CSII group and 38 participants were randomly assigned to the CGM plus MDI group. The study was completed by 36 (97%) of 37 participants in the CGM plus CSII group and 35 (92%) of 38 participants in the CGM plus MDI group. Mean CGM use was 6·7 days per week (SD 0·8) in the CGM plus CSII group and 6·9 days per week (0·3) in the CGM plus MDI group (p=0·86). No participants in the CGM plus CSII group who completed the trial discontinued CSII. Over the follow-up period, mean time in the glucose concentration range of 70-180 mg/dL (3·9-10·0 mmol/L) was 791 min per day (SD 157) in the CGM plus CSII group and 741 min per day (225) in the CGM plus MDI group (adjusted mean treatment group difference: 83 min, 95% CI 17-149; p=0·01). Participants in the CGM plus CSII group had a greater reduction in CGM-measured mean glucose (p=0·005) and hyperglycaemia (on four metrics: p=0·007 for >180 mg/dL [>10·0 mmol/L], p=0·02 for >250 mg/dL [>13·9 mmol/L], p=0·04 for >300 mg/dL [>16·6 mmol/L], and p=0·02 for the area under the curve for 180 mg/dL [10·0 mmol/L]), but also an increase in CGM-measured hypoglycaemia (p=0·0001 for <70 mg/dL [<3·9 mmol/L], p=0·0002 for <60 mg/dL [<3·3 mmol/L], p=0·0009 for <50 mg/dL [<2·8 mmol/L], p=0·0002 for the area over the curve for 70 mg/dL [3·9 mmol/L]). Mean HbA 1c change from baseline to 28 weeks was 0·3% (SD 0·9; 3·3 mmol/mol [SD 9·8]) in the CGM plus CSII group and 0·1% (0·4; 1·1 mmol/mol [4·4]) in the CGM plus MDI group (p=0·32). Severe hypoglycaemia occurred in one participant in the CGM plus MDI group, and diabetic ketoacidosis and severe hyperglycaemia occurred in one participant each in the CGM plus CSII group.Interpretation Our findings show that glycaemic control measured by time in the glucose range of 70-180 mg/dL (3·9-10·0 mmol/L) is improved by initiation of CSII in adults with type 1 diabetes. However, biochemical hypoglycaemia also was increased in the study, which will be important to consider when incorporating these results into clinical practice.Funding Dexcom.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In comparisons of regimens of MDI with BGM (without CGM) vs CSII for T1D, there have been small improvements in A1C, but substantial reductions in severe and nocturnal hypoglycemia.1113,1125–1127”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1126]
Citations
Cites
Continuous glucose monitoring and intensive treatment of type 1 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805017 · Cited by 1,559
Beck, R. W., Riddlesworth, T., Ruedy, K., Ahmann, A., Bergenstal, R., Haller, S., Kollman, C., Kruger, D., McGill, J. B., Polonsky, W., et al. (2017) · JAMA · doi:10.1001/jama.2016.19975 · Cited by 1,185
Self-citationEffectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes
Bergenstal, R. M., Tamborlane, W. V., Ahmann, A., Buse, J. B., Dailey, G., Davis, S. N., Joyce, C., Peoples, T., Perkins, B. A., Welsh, J. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002853 · Cited by 894
Self-citationLind, M., Polonsky, W., Hirsch, I. B., Heise, T., Bolinder, J., Dahlqvist, S., Schwarz, E., Ólafsdóttir, A. F., Frid, A., Wedel, H., et al. (2017) · JAMA · doi:10.1001/jama.2016.19976 · Cited by 705
Self-citationClarke, W. L., Cox, D. J., Gonder-Frederick, L. A., Julian, D., Schlundt, D., & Polonsky, W. (1995) · Diabetes Care · doi:10.2337/diacare.18.4.517 · Cited by 651
Self-citationPickup, J. C., & Sutton, A. J. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02486.x · Cited by 617
Weissberg-Benchell, J., Antisdel-Lomaglio, J., & Seshadri, R. (2003) · Diabetes Care · doi:10.2337/diacare.26.4.1079 · Cited by 551
Pickup, J. C., Freeman, S. C., & Sutton, A. J. (2011) · BMJ · doi:10.1136/bmj.d3805 · Cited by 541
the SWITCH Study Group, Battelino, T., Conget, I., Olsen, B., Schütz-Fuhrmann, I., Hommel, E., Hoogma, R., Schierloh, U., Sulli, N., & Bolinder, J. (2012) · Diabetologia · doi:10.1007/s00125-012-2708-9 · Cited by 494
Pickup, J., Mattock, M., & Kerry, S. (2002) · BMJ · doi:10.1136/bmj.324.7339.705 · Cited by 483
Cited by
Continuous glucose monitoring and metrics for clinical trials: an international consensus statement
Battelino, T., Alexander, C. M., Amiel, S. A., Arreaza-Rubin, G., Beck, R. W., Bergenstal, R. M., Buckingham, B. A., Carroll, J., Ceriello, A., Chow, E., et al. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00319-9 · Cited by 831
Self-citationHeinemann, L., Freckmann, G., Ehrmann, D., Faber-Heinemann, G., Guerra, S., Waldenmaier, D., & Hermanns, N. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30297-6 · Cited by 522
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Self-citationThe relationship of hemoglobin A1C to time-in-range in patients with diabetes
Vigersky, R. A., & McMahon, C. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0310 · Cited by 464
Grunberger, G., Sherr, J., Allende, M., Blevins, T., Bode, B., Handelsman, Y., Hellman, R., Lajara, R., Roberts, V. L., Rodbard, D., et al. (2021) · Endocrine Practice · doi:10.1016/j.eprac.2021.04.008 · Cited by 288
Self-citation
Metadata
- Authors
- Beck, R. W., Riddlesworth, T. D., Ruedy, K. J., Kollman, C., Ahmann, A. J., Bergenstal, R. M., Bhargava, A., Bode, B. W., Haller, S., Kruger, D. F., McGill, J. B., Polonsky, W., Price, D., Toschi, E., Toschi, E., Wolpert, H., Atakov-Castillo, A., Markovic, E., Aronoff, S., Brooks, S., Martinez, G., Mendez, A., Dunnam, T., Bhargava, A., Fitzgerald, K., Wright, D., Khoo, T., Theuma, P., Herrold, T., Thomsen, D., Bergenstal, R., McCann, K., Monk, A., Ashanti, C., Liljenquist, D., Judge, H., Halford, J., Kruger, D., Levy, S., Bhan, A., Cushman, T., Dawson, L., Remtema, H., Wolf, F., Neifing, J., Murdoch, J., Staat, S., Mayfield, T., Ahmann, A., Klopfenstein, B., Joarder, F., Hanavan, K., Castle, J., Aby-Daniel, D., Morimoto, V., DeFrang, D., Wollam, B., McGill, J., Jordan, O., Recklein, C., Kipnes, M., Haller, S., Ryan, T., Bode, B., Boyd, J., Rastogi, N., Lindmark, K., Biggs, W., Sandoval, L., Eifert, R., Cota, B., Nguyen, Q., Martinez, A., Duran, C., Segel, S., Sutton, D., Roura, M., Rosenwasser, R., McElveen, J., Knisely, E., Johnson, A., Odugbesan, A. O., Wardell, K., Paulus, C., Wahlen, J., Winkfield, J., Wahlen, H., Hepworth, E., Winkfield, D., Owens, S., Leichter, S., Evans, E., Konigsberg, S., Rahman, J., Gaudiani, L., Woods, N., Cardozo, J., Wheeler, K., Kane, J., Eubanks, T., Ruedy, K., Beck, R. W., Kollman, C., Riddlesworth, T., Mouse, T., Price, D., Casal, E., Graham, C., & Polonsky, W.
- Affiliations
- Dexcom (United States) (US)
- Oregon Health & Science University (US)
- Washington University in St. Louis (US)
- Diabetes & Glandular Disease Clinic (US)
- Atlanta Diabetes Associates (US)
- Jaeb Center for Health Research (US)
- ORCID
- Venue
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Published
- 2017-09
- Volume
- 5
- Issue
- 9
- Pages
- 700-708
- ISSN
- 2213-8587 (ISSN-L)
- OpenAlex
- W2735783344
- Cited by
- 119
- References
- 16
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 11 · 2023: 12 · 2022: 21 · 2021: 20 · 2020: 15 · 2019: 17 · 2018: 13 · 2017: 4
- FWCI
- 10.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet Diabetes & Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Dexcom
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- type 1 diabetes, insulin pump therapy, multiple daily insulin injections, continuous glucose monitoring, glycemic control, time in range, mean blood glucose, adults with type 1 diabetes, hypoglycemia, diabetes self-management, HbA1c
- MeSH terms
- Adult, Aged, Diabetes Mellitus, Type 1, Drug Administration Schedule, Female, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Insulin, Insulin Infusion Systems, Male, Middle Aged, Blood Glucose Self-Monitoring, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of initiating use of an insulin pump in adults with type 1 diabetes using multiple daily insulin injections and continuous glucose monitoring (DIAMOND): a multicentre, randomised controlled trial. https://app.cochat.ai/papers/10.1016/s2213-8587(17)30217-6
- The paper
- Beck, R. W., Riddlesworth, T. D., Ruedy, K. J., Kollman, C., Ahmann, A. J., Bergenstal, R. M., Bhargava, A., Bode, B. W., Haller, S., Kruger, D. F., McGill, J. B., Polonsky, W., Price, D., Toschi, E., Toschi, E., Wolpert, H., Atakov-Castillo, A., Markovic, E., Aronoff, S., . . . Polonsky, W. (2017). Effect of initiating use of an insulin pump in adults with type 1 diabetes using multiple daily insulin injections and continuous glucose monitoring (DIAMOND): a multicentre, randomised controlled trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(17)30217-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.